title: Creating a pathway over the regulatory chasm: a fresh start.
abstract: With the election over, a clear framework for guiding follow-on biologics to market may soon emerge. But difficult issues of cost, timing, and even terminology are keeping innovators and generic rivals on opposite sides of the fence.
authors.affiliation: Ed Silverman is a writer at the Star-Ledger , in Newark, N.J., and is the blogger behind Pharmalot.com.
authors.forename: Ed
authors.initials: E
authors.lastname: Silverman